InvestorWire NewsRoom


InvestorNewsBreaks – Ocean Biomedical Inc.’s (NASDAQ: OCEA) Joint Venture Partner to Present First Clinical Study Data at 33rd Annual Meeting of APASL
February 29, 2024

InvestorNewsBreaks – Ocean Biomedical Inc.’s (NASDAQ: OCEA) Joint Venture Partner to Present First Clinical Study Data at 33rd Annual Meeting of APASL

Ocean Biomedical (NASDAQ: OCEA), a biopharma company that endeavors to accelerate the development of compelling discoveries from top research scientists, congratulates its joint venture partner, Virion Therapeutics, LLC, a clinical-stage biotechnology company developing T cell-based immunotherapies, for the acceptance of its abstract highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure. The abstract was accepted for late breaker oral presentation at the 33rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver), taking place in Kyoto, Japan, from March 27-31, 2024. “This accepted abstract highlights Virion’s commitment to finding a functional cure for chronically HBV-infected patients – and the first-ever human data for a genetically encoded checkpoint modifier T cell vaccine of any kind. VRON-0200 is uniquely developed to stimulate a patient’s own immune response to the virus. Additionally, its mechanism of action and intramuscular administration were designed to limit safety issues for this novel therapy,” said Dr. Sue Currie, COO of Virion and one of the study authors. “We look forward to sharing these late breaking clinical HBV data at APASL, one of the leading meetings on the treatment of liver diseases in the world.”

To view the full press release, visit

About Ocean Biomedical Inc.

Ocean Biomedical is a Providence, Rhode Island-based biopharma company with an innovative business model that strives to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical intends to deploy the resources and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic to the world. Ocean Biomedical is currently developing five discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team’s goal is to work on solving some of the world’s toughest problems, for the people who need it most. To learn more about the company, visit

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).